BRAF基因突变转移性结直肠癌治疗进展  

Progress in treatment of metastatic colorectal cancer with BRAF mutation

作　　者：史幼梧 贾军[1] Shi Youwu;Jia Jun(Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),VIP-I Gastrointestinal Cancer Division of the Department of Medicine,Peking University Cancer Hospital&Institute,Beijing 100142,China)

机构地区：[1]北京大学肿瘤医院暨北京市肿瘤防治研究所消化道肿瘤VIP-Ⅱ病区,恶性肿瘤发病机制及转化研究教育部重点实验室,北京100142

出　　处：《中国肿瘤临床与康复》2023年第6期333-339,共7页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：BRAF基因突变结直肠癌是一种具有独特临床病理特征的亚型,BRAF突变以BRAFV600E突变最为常见.BRAFV600E突变结直肠癌的疗效和预后较差,晚期一线可选择化疗联合抗血管生成药物的治疗策略,后线治疗采用BRAF抑制剂联合表皮生长因子受体抑制剂方案可为患者带来生存获益.目前BRAFV600E突变转移性结直肠癌的治疗探索包括阻断各种细胞信号传导通路的靶向药物联合以及靶向治疗与免疫治疗联合等治疗策略.文章就BRAF突变转移性结直肠癌的分子生物学特点、临床病理特征以及BRAFV600E突变转移性结直肠癌的治疗进展进行综述.Colorectal cancer(CRC)with BRAF mutation is a subtype with unique clinicopathological characteristics.V600E is the most common type of BRAF mutation and CRC with BRAF V600E mutation has a bad treatment response and poor prognosis:Chemotherapy combined with anti-angiogenic agents is an optional initial treatment in patients with metastatic CRC.The combination of BRAF inhibitor and epidermal growth factor receptor inhibitor had been proved that could bring survival benefits to patients inposterior treatment.At present,combination treatment such as combining inhibitors of various cellular signaling pathways and integrating targeted therapy with immunotherapy are being explored in metastatic CRC with BRAFV600E mutation.The article reviews the molecular biology and clinicopathological characteristics of metastatic CRC with BRAF mutation and research progress in treatment of metastatic CRC with BRAFV600E mutation.

关 键 词：转移性结直肠癌 BRAF 靶向治疗 免疫治疗 

分 类 号：R735.34[医药卫生—肿瘤]